Navigation Links
Caliper Owners Group Meeting Showcases Critical Role of Biopharma and Academic Researchers for Improving Healthcare and Quality of Life
Date:6/25/2010

HOPKINTON, Mass., June 25 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, hosted its 2010 annual Customers Owners Group (COG 2010) meeting on June 9 and 10. This thought-leadership conference is focused on sharing knowledge, insights, and techniques that accelerate the drug discovery and development process, leading to the next generation of breakthrough diagnostics and therapies.

Next Generation Sequencing pioneer Dr. George Church of Harvard Medical School kicked off COG 2010 with a keynote presentation focused on how technological advances in sequencing, coupled with a deeper understanding of the interpretation and clinical utility of genomic data, will revolutionize the healthcare industry.

Kevin Hrusovsky, president and chief executive officer of Caliper, concluded the meeting with a keynote presentation illustrating how next generation tools will revolutionize medicine.  He challenged participants to set goals for themselves and their labs to utilize these tools to increase life expectancy by 10 years by 2020 while controlling healthcare system costs, and to find cures for cancer and heart disease, two leading causes of death in the U.S.  Hrusovsky's vision focuses on three key diagnostic and three key therapeutic themes that will substantially revolutionize medicine. Genome sequencing, biomarkers/MDx, and non-invasive imaging are enabling diagnostic tools that can be deployed both to accelerate preclinical research and to provide faster, more accurate analysis of patient conditions. Vaccines, biotherapeutics, and stem cells are targeted therapeutic tools that will substantially reduce both the incidence and prevalence of disease. Cumulatively, these tools enable personalized medicine, which ensures that each person's health care is guided in a customized manner to achieve an optimal clinical outcome.  Caliper's technologies are playing an increasingly important role in each of these key applied application areas.  

"The discoveries and presentations shared during COG 2010 clearly show the role of Caliper's technologies in enabling experimentation that bridges the gap between in vitro assays and in vivo results," Hrusovsky said. "We are collaborating with our customers to make pioneering experimentation possible by creating solutions that improve data quality, increase throughput, and reduce the cost per data point."

Throughout the meeting, customer presentations focused on how advances in laboratory tools are accelerating experimentation, improving the predictive nature of discovery research, and providing scientists with high quality data throughout the drug development process. This contributes to an increase in the overall success rate of pharmaceutical R&D efforts and helps bring new, cutting-edge treatments to market faster and cheaper.

More than 200 attendees participated in the meeting, held at Caliper's Hopkinton headquarters. The event featured over 35 presentations from researchers representing life sciences companies and institutions, including Pfizer, Bristol Myers Squibb, Biogen Idec, GlaxoSmithKline, Merck, Millennium, Momenta Pharmaceuticals, ArQule, EMD-Merck, New England Biolabs, Epicentre, Covaris, Machery Nagel, Transgenomics, Access Genetics, PhyNexus, SRU Biosystems, Harvard, Stanford, University of North Carolina, Broad Institute, SUNY Upstate, and University of Sherbrooke. Globally over 500 customers have presented and participated in Caliper events this year.

COG 2010 presentations, keynotes and a summary video can be found on Caliper's website at: http://www.caliperls.com/support/caliper-owners-group.htm

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently.  Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling the translation of those results into cures for human disease.  Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions. For more information please visit www.caliperLS.com.

Caliper is a registered trademark of Caliper Life Sciences, Inc.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences to Webcast Investor Session of Open House
2. Caliper Life Sciences to Present at Jefferies 2010 Global Life Sciences Conference
3. Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage
4. Caliper Awarded Additional Task Order for EPA ToxCast Program
5. Caliper Life Sciences to Present at Deutsche Banks 35th Annual Health Care Conference
6. Caliper Life Sciences Launches LabChip(R) XT for Next Generation Sequencing Applications
7. Caliper Life Sciences Launches Living Image(R) 4.0 Software
8. Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems
9. Caliper Life Sciences Launches IVIS(R) In Vivo Imaging System with X-Ray
10. Caliper Life Sciences Reports Second Quarter 2009 Results
11. Caliper Life Sciences Second Quarter 2009 Financial Results Conference Call Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
(Date:6/23/2016)... ... 23, 2016 , ... Velocity Products, a division of Morris ... optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, ... several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity ...
(Date:6/22/2016)... June 22, 2016 Cell Applications, Inc. ... them to produce up to one billion human ... within one week. These high-quality, consistent stem cells ... cells and spend more time doing meaningful, relevant ... proprietary, high-volume manufacturing process that produces affordable, reliable ...
Breaking Biology Technology:
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
Breaking Biology News(10 mins):